• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDRX alert in real time by email
    SC 13G/A 1 ea0221977-13ga1brio_bio.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934*

     

    BIODEXA PHARMACEUTICALS PLC
    (Name of Issuer)
     
    AMERICAN DEPOSITORY SHARES**
    (Title of Class of Securities)
     
    59564R708***
    (CUSIP Number)
     
    November 14, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐   Rule 13d-1(b)

    ☒   Rule 13d-1(c)

    ☐   Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    **Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

     

    ***The CUSIP number applies to the American Depositary Shares of the Issuer.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   59564R708

     

    1.

    Names of Reporting Persons

     

    Brio Capital Master Fund Ltd.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)   ☐

    (b)   ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

     

    167,681 American Depository Shares(1) (2)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    167,681 American Depository Shares (1) (2)

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    167,681 American Depository Shares(1) (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒

     

    See footnote (2) below. (See Instructions)

    11.

    Percent of Class Represented by Amount in Row (9)

     

    .9%(3)

    12.

    Type of Reporting Person (See Instructions)

     

    CO

     

    (1)Brio Capital Management LLC, is the investment manager of Brio Capital Master Fund Ltd. and has the voting and investment discretion over securities held by Brio Capital Master Fund Ltd. Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.

     

    (2)This amount includes American Depository Shares issuable upon exercise of the Warrants.

     

    (3)Percentage calculation is based on the number of ordinary shares outstanding as of November 14, 2024, as reported on the company’s website.

      

    2

     

     

    CUSIP No.   59564R708

     

    1.

    Names of Reporting Persons

     

    Brio Capital Management LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)   ☐

    (b)   ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware, United States

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

     

    167,681 American Depository Shares (4)(5)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    167,681 American Depository Shares (4)(5)

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    167,681 American Depository Shares (4)(5)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒

     

    See footnote (5) below. (See Instructions) 

    11.

    Percent of Class Represented by Amount in Row (9)

     

    .9%(6)

    12.

    Type of Reporting Person (See Instructions)

     

    CO

     

    (4)Brio Capital Management LLC, is the investment manager of Brio Capital Master Fund Ltd. and has the voting and investment discretion over securities held by Brio Capital Master Fund Ltd. Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.

     

    (5)This amount includes American Depository Shares issuable upon exercise of the Warrants.

     

    (6)Percentage calculation is based on the number of ordinary shares outstanding as of November 14, 2024, as reported on the company’s website.

     

    3

     

     

    Item 1(a). Name of Issuer
       
      Biodexa Pharmaceuticals PLC (the “Issuer”)
       
    Item 1(b). Address of the Issuer’s Principal Executive Offices
       
     

    1 Caspian Point, Caspian Way

    Cardiff, CF10 4DQ, United Kingdom.

       
    Item 2(a). Names of Persons Filing
       
      This Schedule 13G is filed jointly by:

     

      Brio Capital Master Fund Ltd.
      Brio Capital Management LLC

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Information with respect to each Reporting Person is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person.

     

    Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:
       
      c/o Brio Capital Management LLC, 100 Merrick Road, Suite 401 W. Rockville Center, NY 11570.
       
    Item 2(c). Citizenship

     

     

    Brio Capital Master Fund Ltd. – Cayman Islands

    Brio Capital Management LLC – United States

     

    Item 2(d). Title of Class of Securities
       
     

    American Depository Shares. Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

       
    Item 2(e). CUSIP Number
       
      59564R708
       
    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

      

      ¨ (a)  Broker or Dealer registered under Section 15 of the Exchange Act.
         
      ¨ (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
         
      ¨ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
      ¨ (d) Investment company registered under Section 8 of the Investment Company Act.

     

      ¨ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
         
      ¨ (f)  An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
         
      ¨ (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).
         
      ¨ (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
      ¨

    (i) A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

         
      ¨ (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).
         
        Not applicable

     

    4

     

     

    Item 4.

    Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference.

     

    Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not Applicable 
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not Applicable
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE:   November 20, 2024

     

      Brio Capital Master Fund Ltd.,
      a Cayman Islands Exempted Company
         
      By: Brio Capital Management LLC, its Investment Manager
         
      By: /s/ Shaye Hirsch
        Name:   Shaye Hirsch
        Title: Managing Member
         
      Brio Capital Management LLC,
      a Delaware limited liability company
         
      By: /s/ Shaye Hirsch
        Name: Shaye Hirsch
        Title: Managing Member

     

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations

    (See 18 U.S.C. 1001)

      

    6

     

    Get the next $BDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDRX

    DatePrice TargetRatingAnalyst
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BDRX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/27/25 5:16:21 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/27/25 5:16:22 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/27/25 5:15:40 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care